Analysis of VMAT2 binding after methamphetamine or MPTP treatment: Disparity between homogenates and vesicle preparations

Journal of Neurochemistry

Volumn 74, Issue 5, 2000, Pages 2217-2220

  Hogan, Kelly A ^a   Staal, Roland G W ^a   Sonsalla, Patricia K ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Dihydrotetrabenazine binding; Dopamine nerve terminals; Methamphetamine; MPTP; Striatal homogenates; Vesicular monoamine transporter

Indexed keywords

BRAIN MONOAMINE; CARRIER PROTEIN; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; LIGAND BINDING; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SYNAPSE VESICLE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; HISTOLOGICAL TECHNIQUES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; MICE; NEUROPEPTIDES; SYNAPTIC VESICLES; SYNAPTOSOMES; TETRABENAZINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

ANIMALIA;

EID: 0034007741     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0742217.x     Document Type: Article

References (21)

1. Berman S. B., Zigmond M. J., and Hastings T. G. (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67, 593-600.
2. Brown J. M., Hanson G. R., and Fleckenstein A. E. (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 74, 2221-2223.
3. DelleDonne K. T. and Sonsalla P. K. (1994) Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271, 1320-1326.
4. Fleckenstein A. E., Metzger R. R., Wilkins D. G., Gibb J. W., and Hanson G. R. (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282, 834-838.
5. Frey K. A., Kilbourn M. R., and Robinson T. (1997) Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur. J. Pharmacol. 334, 273-279.
6. German D. C., Nelson E. L., Liang C. L., Speciale S. G., Sinton C. M., and Sonsalla P. K. (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5, 299-312.
7. Kramer J. C., Fischman V. S., and Littlefield D. C. (1967) Amphetamine abuse: pattern and effects of high doses taken intravenously. JAMA 201, 89-93.
8. 3H]2-carbomethoxy-3-(4-fluorophenyl)tropane. Mol. Pharmacol. 36, 518-524.
9. 11C]WIN-35,428. J. Neurosci. 18, 8417-8422.
10. Morgan M. E. and Gibb J. W. (1980) Short-term and long-term effects of methamphetamine on biogenic amine metabolism in extra-striatal dopaminergic nuclei. Neuropharmacology 19, 989-995.
11. O'Callaghan J. P. and Miller D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270, 741-751.
12. Pu C. and Vorhees C. V. (1993) Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Brain Res. Dev. Brain Res. 72, 325-328.
13. Ricaurte G. A., Guillery R. W., Seiden L. S., Schuster C. R., and Moore R. Y. (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235, 93-103.
14. Seiden L. S., Sabol K. E., and Ricaurte G. A. (1993) Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 32, 639-677.
15. Sonsalla P. K. and Nicklas W. J. (1992) MPTP and animal models of Parkinson's disease, in Handbook of Parkinson's Disease (Koller W. C., ed), pp. 319-340. Marcel Dekker, New York.
16. Sonsalla P. K., Youngster S. K., Kindt M. V., and Heikkila R. E. (1987) Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J. Pharmacol. Exp. Ther. 242, 850-857.
17. Sonsalla P. K., Nicklas W. J., and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398-400.
18. 3H]-dopamine uptake. J. Pharmacol. Exp. Ther. 280, 1432-1444.
19. 3H]-Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 68, 955-962.
20. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18, 419-427.
21. Wilson J. M., Kalasinsky D. S., Levey A. I., Bergeron C., Reiber G., Anthony R. M., Schmunk G. A., Shannak K., Haycock J. W., and Kish S. J. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 6, 699-703.